

## Special Issue

# Biomarkers for Heart Failure Diagnosis, Prognosis and Guidance of Therapy

### Message from the Guest Editors

Circulating biomarkers play a central role in determining the diagnosis and prognosis of heart failure (HF). The most well-established category of biomarkers is natriuretic peptides, which are strongly recommended by current guidelines in multiple settings of HF. Several other biomarkers have also been investigated in relation to HF, of which many are in clinical use, including cardiac troponins and soluble ST2. Several candidate proteins are being investigated using emerging data from large-scale analyses, such as proteomics, to improve the ability to diagnose HF, predict outcomes, and accurately monitor therapy. Dedicated analyses of patients with HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction are warranted as these conditions are distinct with respect to clinical characteristics and biomarker profiles. In the current Special Issue, we provide state-of-the-art reviews, perspectives, and original manuscripts by experts in the field about the latest evidence from biomarker research in HF.

---

### Guest Editors

Dr. Peder Langeland Myhre

1. Department of Cardiology, Division of Medicine, Akershus University Hospital, 1474 Lørenskog, Norway
2. Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0315 Oslo, Norway

Dr. Thomas A. Zelniker

Division of Cardiology, Medical University of Vienna, 1090 Vienna, Austria

---

### Deadline for manuscript submissions

closed (31 March 2024)



## Journal of Cardiovascular Development and Disease

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.3  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/131413](https://mdpi.com/si/131413)

*Journal of Cardiovascular  
Development and Disease*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcdd@mdpi.com](mailto:jcdd@mdpi.com)

[mdpi.com/journal/  
jcdd](https://mdpi.com/journal/jcdd)





# Journal of Cardiovascular Development and Disease

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.3  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
jcdd](https://mdpi.com/journal/jcdd)



## About the Journal

### Message from the Editor-in-Chief

The primary goal of the *Journal of Cardiovascular Development and Disease* (JCDD, ISSN 2308-3425) is to provide cardiovascular scientists a platform to publish their work in a quick and efficient way. Topics can range from studies designed to decipher the events underlying early heart development to studies focusing on the origins of congenital and acquired heart disease. Papers submitted to *JCDD* undergo a fast, yet thorough, peer-review process. In this process, we will apply strict ethical policies and standards. *JCDD* guarantees fast dissemination of results to a large scientific audience.

---

### Editor-in-Chief

Prof. Dr. Thomas Brand  
National Heart & Lung Institute, Imperial College London, South  
Kensington Campus, London SW7 2AZ, UK

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Cardiac and Cardiovascular Systems) /  
CiteScore - Q2 (General Pharmacology, Toxicology and  
Pharmaceutics)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 24.7 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the second half of 2025).